Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)
Keyword(s):
Keyword(s):
2018 ◽
Vol 48
(9)
◽
pp. 855-859
◽
Keyword(s):
2021 ◽
Keyword(s):
2019 ◽
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS636-TPS636
Keyword(s):
Keyword(s):
2013 ◽
Keyword(s):